Zhou's team found that CRISPR-mediated inhibition of EZH2 was able to upregulate MHC class I expression and CD8 + T-cell proliferation in head and neck squamous cell carcinoma (HNSCC) [54]. Here, EZH2 is linked to head and neck squamous cell carcinoma.